Patients aged 18 years and older with metastatic soft-tissue sarcomas , an Eastern Cooperative Oncology Group performance status of 0-2 , and who had previously received treatment with anthracycline and ifosfamide were randomly assigned ( 1:1 ) to intravenous infusion of ombrabulin 25 mg/m ( 2 ) plus cisplatin 75 mg/m ( 2 ) or intravenous infusion of placebo plus cisplatin 75 mg/m ( 2 ) every 3 weeks .